中文摘要：

目的 观察通痹化纤方对肺纤维化大鼠肺功能及肿瘤坏死因子-α（TNF-α）、尿激型纤溶酶原激活剂（uPA）和纤溶酶原激活剂抑制剂-1（PAI-1）表达的影响,探讨该方治疗肺纤维化大鼠的作用机制.方法 将70只大鼠随机分为空白组、模型组、激素组、中药组,气管内注射博来霉素造成肺纤维化大鼠模型,造模后28天予以相应药物灌胃给药,连续给药21天.检测各组大鼠肺组织病理形态学、肺功能、血清及支气管肺泡灌洗液uPA和PAI-1水平、血清TNF-α水平的变化.结果 模型组呈中重度肺纤维化改变,中药和激素组肺泡炎和肺纤维化程度均较模型组明显减轻;与模型组比较,中药和激素组TNF-α水平明显降低（P〈0.05）;与空白组比较,其余各组大鼠血清uPA水平明显降低（P〈0.05）;与空白组比较,模型组大鼠MVV水平明显降低（P〈0.05）;与空白组比较,模型组大鼠Cydn水平明显降低（P〈0.05）,与模型组比较,中药和激素组Cydn水平明显升高（P〈0.05）;与空白组比较,模型组大鼠RL水平明显升高（P〈0.05）,与模型组比较,中药组RL水平明显降低（P〈0.05）;与空白组比较,模型组大鼠RE水平明显升高（P〈0.05）.结论 通痹化纤方可能通过降低肺纤维化大鼠血清中TNF-α水平,改善肺纤维化大鼠Cydn及RL,从而延缓肺纤维化的进程.

英文摘要：

Objective To investigate the mechanism of the treatment of pulmonary fibrosis in rats through examining the effect of Tongbi Huaxian Decoction on expression of lung function of rats with pulmonary fibrosis and tumor necrosis factor-α （TNF-α） , urokinase-type plasminogen activator （uPA） and plasminogen activator inhibitor-1 （ PAI-1 ）. Methods Seventy rats are randomly divided into the untreated group, the control group, the hormone treatment group, and the Chinese herbs treatment group. We make the pulmonary fibrosis rat model by intratracheal injection of bleomycin. We start the treatment by giving the appropriate drugs on gavage for 21 continuous days 28 days after the start of the model. We examine lung tissue pathology, changes in lung function, serum and bronchoalveolar lavage fluid of uPA and PAI-1 levels, and serum levels of TNF-α level for each group. Results The control group has severe pulmonary fibrosis while the Chinese herbs and hormone groups have significantly less severe alveolitis and pulmonary fibrosis. Compared to the control group, both treatment groups have significantly lower TNF-α level （ P〈0. 05 ）. Compared with the untreated group, all other groups have significantly lower serum uPA level （P〈 0.05 ）. Compared with the untreated group, the control group has significantly lower MVV level （P〈0.05）. Compared with the untreated group, the control group has significantly lower Cydn level （P〈0. 05） while both treatment groups have significantly higher Cydn level （P〈0.05）. Compared with untreated group, the control group has significantly higher RL level （ P〈0.05 ） while the Chinese medicine treatment group has significantly lower RL level （ P〈0.05 ）. Compared with the untreated group, the control group has significantly higher RE level （ P〈0.05 ）. Conclusion Tongbi Huaxian Decoction may improve Cydn and RL in rats with pulmonary fibrosis through reducing serum TNF-α levels, thereby delaying the process of pulmonary fibrosis.